CHSJ

Curr Health Sci J, vol. 44, no. 2, 2018

EGFR Immunoexpression in Malignant Serous and Mucinous Ovarian Tumors

[Original paper]

A-E. CIRSTEA(1), A.E. STEPAN(2), R.E. ZAVOI(3), C.E. SIMIONESCU(2)


(1)PhD Student, University of Medicine and Pharmacy of Craiova, Romania,
(2)Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania,
(3)Department of Forensic Medicine, University of Medicine and Pharmacy of Craiova, Romania


Abstract:

The epithelial growth factor receptor (EGFR) is involved in various stages of cancer growth such as tumor initiation, angiogenesis and metastasis, being an attractive target for oncogenic therapy. The present study aims to evaluate the EGFR expression in 54 cases of serous and mucinous ovarian borderline tumors and carcinomas. EGFR expression was present in more than half of the investigated tumors, more frequently in carcinomas than in borderline tumors, especially in the serous type. The highest values of the final staining score (FSS) were observed only in serous carcinomas in the advanced stages of the disease. As a result of frequent expression of EGFR in ovarian tumors, it is necessary to monitor EGFR inhibitors for ovarian cancer therapy, but probably after establishing more rigorous selection and stratification criteria for patients.


Keywords: malignant ovarian tumors, EGFR



Corresponding: Alex Emilian Stepan, Department of Pathology, University of Medicine and Pharmacy of Craiova, 66 1 May Avenue, 200628 Craiova, Romania, e-mail: astepan76@yahoo.com


DOI 10.12865/CHSJ.44.02.06 - Download PDF
current issue cover Download cover
Download contents

Journal archive